TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07903701: A Phase II/III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of SIM0811 Injection in Patients With Acute Ischemic Stroke

Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd. · Phase: PHASE2/PHASE3 · Area: CNS_NEUROLOGY · Target Enrollment: 1092 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$15,147,520

Rescue Site Savings

+$9,987,896

Unlock Full NCT07903701 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07903701 Rescue Dossier →